Noted Neurologist Holds News Conference in Mexico to Reveal Study Linking RSHO-X™ to Improvements in Seizure Frequency

[vc_row][vc_column][vc_column_text]A press conference held this past Tuesday in Mexico announced the positive results of a groundbreaking epilepsy study on the effects of CBD on seizures. Conducted by renowned pediatric neurologist Dr. Saul Garza Morales, the study took a look at patients who have used THC-free RSHO-X™ to treat their seizures and recorded the results, tracing the effects of the CBD oil.

Between January of 2016 and February of 2017, Dr. Garza Morales studied 45 patients diagnosed with Lennox-Gastaut Syndrome, a neurological disorder causing seizures that is often diagnosed in young children. The patients enrolled in the study continued to experience various types of seizures per day, despite taking at least three anti-epileptic drugs. Some patients removed themselves from the research for various reasons, leaving 39 cases at the end of the study. These patients took RSHO-X™ pure CBD oil in doses of up to 5-7 mg of CBD per kg of body weight for at least 6 months after the study began.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_single_image image=”21892″ img_size=”1200×800″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text]The results of the study revealed a significant reduction in the frequency of seizures for patients with Lennox-Gastaut. A 50 percent or greater reduction in seizures was obtained in 33 out of 39 or 84 percent of the cases, while 53 percent of the cases achieved an overall reduction in seizure activity of over 75 percent. A complete elimination of seizures for at least 4 months was achieved in 7 cases (17 percent of the patients), which the study characterizes as an outstanding result for this type of patient. The seizures that responded best from the use of pure CBD were atonic, absent, and generalized tonic, reaching a reduction from 30 up to 100 percent.

“We wanted to reduce their pain and suffering due to their seizures and crisis, but 90% of their families reported that they had improved other things like alertness and social interaction or attention processes with their family,” Dr. Garza Morales revealed during the press conference.  “Therefore, it seems that this substance – that is still not considered a medicine – could have additional benefits for children with this type of disease and would undoubtedly help them to live a better quality of life.”

Other benefits were recorded in 89 percent of patients, including increased alertness in 43 percent of patients, improved social interaction in 40 percent, and increased attention in 30 percent. To help verify observed results, all patients had imaging studies (CT or MRI) and at least two EEG studies, giving Dr. Garza brain imaging data to examine alongside observable changes and seizure numbers. Most importantly, zero percent of the participants in the study experienced serious adverse effects.

In his presentation, Dr. Garza Morales continued, “The scope of cannabidiol for medical use is gigantic, and I believe that Mexico should be more open regarding the use of this products in a rational way. The first thing we need to do is to remove the ban, so doctors like us can experiment with this. If we provide them with scientific information as we are doing right now, the government will be able to make rightful decisions, and we will be able to benefit more children. That’s the message.”

The press conference and the results of the study were widely covered in Mexico’s national media, with reporters from a range of outlets, like Frontera, Reforma, and El Universal, eager to ask Dr. Garza Morales questions about his study, the first of its kind in Mexico.

During the press conference, Raul Elizalde of the Por Grace Foundation said, “the most important part this study is that it’s the first study in Mexico. There is nothing similar out there yet. It’s the first study done to a select population, the Lennox Gastaut population, in the world, is one of the first, if not the first, that uses 100% pure cannabinoid or CBD, in the world, so this is a watershed not only for general investigation, for clinical investigation, but also for Mexico.”

Read about the developments of Medical Marijuana, Inc.’s portfolio of companies on our news feed or learn more about the connection between Lennox-Gastaut Syndrome and CBD on our education page. [/vc_column_text][/vc_column][/vc_row]